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Abstract: Management of solid tumors involving the skull base are primarily managed with surgery and
radiation, though proximity to important vascular and neuroanatomic structures often limit the extent
of resection and permissible radiation dose. Meningiomas are the most common primary brain tumor in
adults, and although the majority of skull base meningiomas are low-grade, their location in proximity to
critical anatomical structures precludes aggressive surgical resection, and larger tumors are often resistant
to radiation treatment. In patients with clinically aggressive, unresectable meningiomas, several molecular
biomarkers of angiogenesis, as well as genetic mutations (SMO, AKT1, PIK3CA, KLF4, POLR2, SMARCE1,
and TRAF7), have been shown to play a crucial role in the pathophysiology of these tumors. Pituitary
adenomas are commonly slow growing tumors that are amenable to surgical resection, but tumors with
higher Ki67 proliferative indices are associated with an increased risk of relapse and resistance to standard
therapies. Chemotherapeutic agents and checkpoint inhibitors have been trialed, albeit with limited success,
to treat these aggressive pituitary adenomas. Craniopharyngiomas are categorized as adamantinomatous
and papillary subtypes, each with unique molecular mechanisms that drive pathogenesis of these tumors,
and have introduced the possibility that targeted therapies may be developed for improved neurologic and
endocrinological outcomes. Skull base tumors that exhibit recurrence despite surgical resection and radiation
treatment pose a unique challenge, and systemic agents offer a non-invasive option of treating tumors that
are refractory to conventional approaches. Recent insights into the molecular aberrations that elucidate
the pathophysiology of these difficult-to-treat tumors have provided potential therapeutic targets for drug
delivery. In this review, the authors discuss promising therapies and current knowledge gaps needed for the
development of effective targeted agents for meningioma, pituitary adenoma, and craniopharyngioma.
Keywords: Chemotherapy; immunotherapy; cranial base tumor; vascular endothelial growth factor (VEGF);
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Introduction
Tumors of the skull base region are frequently slowgrowing and benign, though intervention is often pursued
when symptoms occur. These can be challenging to manage
and often require a multidisciplinary approach to optimize
outcome and quality of care. Surgery is central to treatment;
however, complete resection may be precluded by nearby
critical vasculature and neuroanatomic structures such as
cranial nerves and, in time, the residual tumor may grow.
Radiation is beneficial and frequently used in unresectable
or residual tumors, but its use is also limited in multiply
recurrent tumors.
Systemic agents such as chemotherapy have been explored
in the past and generally have been ineffective, though
improved knowledge of tumor biology has led to promising
developments in systemic options. In this review, we
discuss the current molecular and genetic understanding of
meningiomas, pituitary adenomas, and craniopharyngiomas
as it relates to the development of targeted therapy. We
present the following article in accordance with the
NARRATIVE REVIEW reporting checklist (available at
http://dx.doi.org/10.21037/cco-20-168).
Methods
A literature search of PubMed was performed to identify
publications—including basic science research, clinical
studies, and case reports—pertaining to skull base
meningiomas, pituitary adenomas, and craniopharyngiomas
that are resistant to standard surgical and radiation therapy.
No publication limits were applied, and no inclusion or
exclusion criteria were implemented for the literature
search. The authors provide a narrative summary of the
findings and implications of these studies, and how they
pertain to improving the clinical care of our own patients
with these pathologies.
Meningiomas
Meningiomas are the most common type of primary brain
tumors in adults (1). The tumors originate from progenitor
cells in the arachnoid layer of the meninges that envelop
the brain and spinal cord and their clinical presentation is
diverse: 30% present with seizures due to mass effect along
the cerebral convexity or parasagittal region, and an equal
percentage may present with symptoms such as impaired
hearing, loss of smell, or visual changes from encroachment
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of the skull base (2). Meningioma behavior can be predicted
partly by histological grade (3-5). The current World
Health Organization (WHO) defines three grades which
correspond to recurrence risk based on features including
nuclear atypia, mitotic activity, invasion of adjacent
structures, and presence of necrosis (6). Furthermore, each
grade is subdivided into a number of subtypes, some of
which have a predilection for the skull base. Approximately
80% of meningiomas are classified as benign (grade I) with
a low rate of recurrence (7–20%) (6-8). The remainder are
classified as either atypical (grade II) or anaplastic (grade
III) and are associated with significantly shorter recurrencefree intervals and higher mortality rates (40–70%) (9-12).
Surgical intervention is often the first step in the
management of large or symptomatic tumors. Gross total
resection (GTR) is associated with better local control and
progression-free survival compared to subtotal resection
(STR), independent of grade (13,14). However, complete
removal is not always feasible due to a tumor’s proximity
to critical vessels or eloquent brain structures, which is
commonly the case in the skull base region. In selected
patients, particularly those with clinically aggressive,
unresectable meningiomas, radiation can be employed in
either adjuvant or primary settings in hopes of improving
local control over observation alone. Both fractionated
external beam radiation (EBRT) and stereotactic radiation
(SRS) have been used, and the choice of delivery depends
on the size of the target and tumor grade. SRS is a widely
accepted technique for small grade I or II lesions, while
EBRT is recommended for grade III meningiomas which
require larger doses (50–60 Gy) to achieve local control
(15-17). Yet a small subset of these patients remains
refractory to standard intervention; thus, numerous
systemic agents have been explored, including hormone
receptor inhibitors, somatostatin analogs, and conventional
chemotherapy, with none demonstrating reproducible
benefit (18-24). As molecular and genomic techniques
advance, so does our understanding of tumor biology and
potential targets for therapeutic intervention (25,26).
Aberrations in cell signaling pathways can initiate
downstream effects that contribute to the development
of meningiomas. Clarifying which growth factors and
downstream signaling pathways are critical to the
pathogenesis can be challenging and continues to evolve.
Vascular endothelial growth factor (VEGF) and plateletderived growth factor (PDGF) have been implicated in
meningioma growth and are potential therapeutic targets.
Meningiomas are highly vascularized and express
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Figure 1 A 57-year-old man with multiply recurrent WHO grade II meningioma who had undergone three resections and three courses of
radiation to multiple tumor sites since initial diagnosis in 2013. (A) Surveillance MRI one day after resection of a left temporal recurrence.
(B) Baseline brain MRI prior to initiation of bevacizumab (10 mg/kg intravenously every 14 days) and everolimus (10 mg orally daily).
Note interval growth of left cerebellopontine meningioma (arrow). (C) Surveillance scan after one year on combination therapy. The
cerebellopontine meningioma has decreased somewhat in size, and no new tumors had developed in the interim.

angiogenic factors including VEGF. Meningioma extracts
have been shown to induce endothelial chemotaxis
and capillary-like tube formation in vitro, and positive
correlation between VEGF content and meningioma
grade has been demonstrated though not with vascularity
or invasiveness (27-29). VEGF is also involved in the
development of peritumoral edema, which is one cause
of morbidity in high grade meningiomas (30). Antibodies
against VEGF may be effective in controlling symptomatic
edema and tumor growth. In one retrospective study,
bevacizumab (a humanized monoclonal antibody against
VEGF-A) was most effective in slowing tumor growth
and reducing peritumoral edema when compared to
other systemic therapies such as cytotoxic chemotherapy,
somatostatin analogues, and tyrosine kinase inhibitors (31).
A phase 2 single-arm study evaluating the effect of
bevacizumab in combination with everolimus, an inhibitor
of mammalian target of rapamycin (mTOR), in refractory,
progressive intracranial meningioma demonstrated
favorable results (Figure 1) (32). Though the study was
terminated early due to slow accrual, 88% [15/17] of the
patients who received study treatment had stable disease;
six of these 15 patients had stable disease beyond a year.
Median progression-free survival (mPFS) was higher in
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patients with grade II and III meningiomas (22 months)
compared to grade I (17.5 months). The treatment was
fairly well tolerated, as grade 3 and higher toxicities were
uncommon. However, the small sample size was small and
the results require confirmation with larger trials. Results of
a prospective phase 2 trial of single-agent bevacizumab in
patients with recurrent or progressive meningiomas closed
to accrual are forthcoming (NCT01125046).
There is also evidence suggesting the importance of
PDGF in meningioma cell growth and provide rationale
for testing PDGF inhibitors in patients with progressive or
recurrent meningiomas (33-36). The therapeutic potential
of imatinib mesylate, a PDGF receptor (PDGFR) inhibitor,
was evaluated in a phase 2 study conducted by the North
American Brain Tumor Consortium (NABTC 01-08).
The oral agent was generally well tolerated, though
the efficacy data were disappointing. Of the 19 patients
evaluable for response, 10 patients progressed at the first
scan and 9 had stable disease (37). In another phase 2 study,
the combination of imatinib and hydroxyurea was modest
at best in that only 30% [4/13] of patients with grade II
or III meningiomas achieved stable disease longer than
6 months (38). Thus, there is increasing attention to the
development of novel and multi-targeted agents. Sunitinib
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is a small molecule multi-targeted receptor tyrosine kinase
(RTK) inhibitor that targets VEGF receptor (VEGFR)
and platelet-derived growth factor receptor (PDGFR), and
appears to be active even in heavily pre-treated patients with
high-grade meningioma; however, toxicity is a concern.
In a phase 2 trial, 42% were alive and without disease
progression at 6 months (PFS-6), though 60% experienced
a severe adverse event (39). Vatalanib, another multitargeted RTK inhibitor, demonstrated a PFS-6 of 54.4%
for grade II and III meningiomas combined, though since
the study was powered for grade I meningiomas it is unclear
whether the phase 2 trial was positive and remains a major
study limitation (40).
In contrast to the amount of work focused on
molecular targets, efforts to understand genomic drivers
of meningioma growth have increased. The most frequent
genetic alteration in meningioma tumorigenesis involve
mutations or loss of heterozygosity of the tumor suppressor
gene NF2, which encodes the protein merlin and is located
on chromosome 22. Individuals affected by germline
mutations of NF2 develop neurofibromatosis type 2
(NF2) and are predisposed to developing meningiomas
among other benign tumors such as schwannomas and
ependymomas. Although sporadic meningiomas are by far
more common, they too are often driven by this mutation,
which is associated with fibrous or transitional (WHO
grade I) and are more frequently found along the cerebral
convexities than skull base (41). Merlin is involved in key
signaling pathways such as mTOR that regulate cell shape,
growth, and adhesion. In merlin-deficient meningioma
cells, cell proliferation and survival are increased as
a consequence of deregulated downstream effects of
mammalian target of rapamycin complex 2 (mTORC1)
and mTORC2 (42,43). In pre-clinical studies, mTORC1
inhibitors such as everolimus and temsirolimus, and the dual
mTORC1 and mTORC2 inhibitor vistusertib (AZD2014)
demonstrate promising activity against the growth of
meningioma cells and have warranted further study in
humans. In a phase II trial, the combination of bevacizumab
(10 mg/kg IV every 14 days) and everolimus (10 mg
PO daily) produced stable disease (SD) in 15/17 (88%)
of patients; 6 patients had SD for over 12 months (32).
The efficacy of vistusertib in patients with recurrent,
progressive, or symptomatic meningiomas is currently
under investigation in two phase II trials (NCT03071874,
NCT02831257). In the single-center, open-label study
of patients with NF2 and progressive or symptomatic
meningiomas, 18 patients received vistusertib 125 mg BID
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for two consecutive days each week. Radiographic response,
defined as a 20% decrease from baseline, was seen in 5–10%
of schwannomas and meningiomas, though 17% of target
meningiomas progressed. Furthermore, seven patients
(39%) elected to discontinue treatment due to intolerable
side effects including fatigue, anorexia, nausea, vomiting,
rash, and mucositis (Plotkin S, 2018, unpublished data).
The relationship between tumor regression and activation
of TORC1/2 pathways has yet to be clarified.
Next-generation sequencing has made it possible to
identify several recurrent mutations in genes other than
NF2, including SMO, AKT1, PIK3CA, KLF4, POLR2,
SMARCE1, and TRAF7, which are mutually exclusive
with NF2. Meningiomas harboring these mutations also
demonstrate mutant-specific locations in the skull base and
histological subtypes (44-49). The majority of SMO, AKT1,
and PIK3CA-mutant meningiomas occur in the anterior
skull base and are strongly associated with the grade I
meningothelial subtype (50). Smoothened (Smo), which
is encoded by SMO, is a transmembrane protein integral
to the Hedgehog (Hh) signaling pathway and plays a key
role in embryogenesis. Inhibition of Smo by the smallmolecule drug vismodegib is currently under investigation
in combination with a novel FAK inhibitor GSK2256098
(NCT02523014).
AKT1 encodes the enzyme RAS-alpha serine/
threonine-protein kinase and is activated through the
phosphatidylinositol-3 kinase (PI3K)/Akt/mTOR pathway
to suppress apoptosis. Grade I meningiomas which
harbor activating mutations of AKT E17K are characterized
by shorter time to recurrence compared to AKT1 wildtype meningiomas (51). A multicohort basket study of
patients with AKT1-mutant solid tumors demonstrated
that treatment with the pan-Akt inhibitor AZD5363 is safe
and effective (52). Although patients with meningiomas
were not included in this study, Weller et al. reported an
encouraging case in which a patient with multiply recurrent,
meningothelial meningioma metastatic to the lung achieved
stable disease of multiple tumor sites after 17 months of
salvage AZD5363 (given 480 mg twice daily in a four days
on/three days off schedule). Further exploration of targeted
therapy in this subgroup of meningiomas is warranted (53).
Approximately 7% of NF2 wild-type meningiomas
involve PIK3CA, which is mutually exclusive with SMO and
AKT1, and approximately 25% harbor mutations in tumor
necrosis factor receptor-associated factor 7 (TRAF7), which
is involved in ubiquitination and can co-occur with AKT1
or Krüppel-like factor 4 (KLF4) gene (48,54). Both TRAF7
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and KLF4 occur in secretory meningioma (WHO grade
I) and tend to be located in the petroclival or midline skull
base. Currently the tumorigenic roles of TRAF7 or KLF4
are unclear, and warrant further study before effective
targeted agents can be developed.
In contrast to grade I meningiomas, grade II and III
meningiomas exhibit fewer somatic targetable mutations
such as SMO, AKT1, or PIK3CA. Instead, higher grade
meningiomas are more likely to demonstrate high mutational
burden, high-frequency microsatellite instability (MSI-H),
and mismatch repair (MMR) deficiency from copy number
alterations. Compared to specific driver alterations, these
are more challenging to target selectively and may respond
more favorably to a broader approach. The investigation
of immunotherapy such as programmed death-1 receptor
(PD-1) blockade is supported by a number of observations
of high-grade meningiomas: a number of mutations are
predicted to be immunogenic, expression of PD-1 and its
ligand (PD-L1) is increased, and the microenvironment
of meningiomas contain a selected, antigen-experienced
effector T-cell population enriched by those expressing
markers of an exhausted phenotype (44,55-57). Several
phase II clinical trials are actively recruiting to assess the
efficacy of checkpoint inhibitors such as pembrolizumab,
nivolumab, and ipilimumab in recurrent or residual highgrade meningiomas (NCT02648997, NCT03279692,
NCT03604978, NCT03173950).
While surgery and radiation remain central to the initial
management of enlarging, symptomatic meningiomas,
improved understanding of the underlying tumor biology
has refined the options for systemic therapy. The agent
of choice will likely depend on molecular and genetic
profiling, as the response of high-grade meningiomas to
highly selective agents is not expected to be as favorable as
a subset of non-NF2-mutant WHO grade I meningiomas
might. Regardless, early data are promising and give hope
to controlling the disease in patients who have exhausted all
other options.
Pituitary adenomas (PA)
PA account for approximately 10–20% of primary
intracranial tumors and may cause clinical symptoms
either due to hormonal hypersecretion or compression of
surrounding structures including the optic nerves, chiasm,
and cavernous sinuses. The majority of these tumors are
benign and slow growing and are highly treatable with
standard therapies including surgical resection and adjuvant
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radiation therapy. While surgical resection via either a
transsphenoidal or transcranial route continues to be the
mainstay of treatment for most symptomatic pituitary
adenomas, the extent of resection is highly dependent on
a number of factors including tumor size, consistency, and
invasion into the parasellar and suprasellar areas. Following
subtotal resection, 50–60% of adenomas will continue to
progress and even after apparent gross total resection, tumor
recurrence may occur in up to 30% of cases with longterm follow-up (58-62). Adjuvant radiation therapy is often
used for the treatment of residual and recurrent pituitary
adenomas and is typically delivered using stereotactic
radiosurgery (SRS), conventional conformal radiotherapy,
or fractionated stereotactic radiotherapy (FSRT). The goals
of radiation therapy are typically to achieve tumor control
for non-functioning adenomas (NFPA) and tumor control
with endocrine remission for hormone-secreting functional
adenomas. SRS is the most common modality used to treat
recurrent pituitary adenomas with tumor control rates of
94–100% at 5 years and 76–87% at 10 years of follow-up
for NFPA. SRS is typically delivered in a single session with
a marginal dose of 12–18 Gy. Post-radiation neurological
deficits and hypopituitarism following SRS may result in
up to 7% and 39% of patients, respectively (63). Additional
potential complications of radiation therapy include
symptomatic radiation necrosis, secondary neoplasms, and
radiation-induced vasculopathy. Radiation therapy also
plays an important role in inducing hormonal remission for
recurrent functional adenomas resistant to medical therapies
and not amenable to further surgery. Endocrine remission
rates for ACTH-secreting adenomas with SRS range from
28–70% with higher radiation doses necessary to induce
remission compared to those necessary for tumor control
with NFPA.
A small subset of pituitary tumors is classified as
aggressive pituitary adenomas (APA) based on their clinical
presentation and resistance to standard surgical, radiation,
and medical therapies (64). A clear definition for APA
remains controversial, however, the most recent 4th edition
of the WHO Classification of Tumors of the Pituitary Gland
(2017) recognizes the importance of increased mitotic count,
high Ki67 proliferative index (>3%), and tumor invasion
as pathologic markers of clinically aggressive adenomas
with an increased risk of relapse and resistance to standard
therapies (Figure 2) (65,66). Additionally, several subtypes
of pituitary neuroendocrine tumors with a high probability
of recurrence have been designated including silent
corticotroph adenomas, sparsely granulated somatotroph
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Figure 2 Hormone-secreting pituitary macroadenoma, refractory to multi-modality therapy. (A) Coronal MRI with contrast demonstrating
a prolactin-secreting pituitary macroadenoma with right cavernous sinus invasion (*). (B) Despite dopamine agonist therapy, fractionated
stereotactic radiotherapy and transsphenoidal surgical resection, the macroadenoma continued to progress encasing the right carotid artery
(**) and compressing the optic chiasm (arrow) resulting in visual loss.

adenomas, lactotroph adenomas in med, Crooke’s cell
adenoma, and plurihormonal Pit-1-positive adenomas. This
new pathologic classification should enable more accurate
tumor subtyping and improved prediction of aggressive
clinical behavior to better assess and guide our therapies.
The 2017 WHO guidelines continue to define pituitary
carcinomas by the presence of non-contiguous craniospinal
or systemic metastases as pituitary carcinomas and adenomas
are histologically indistinguishable (Figure 3). Fortunately,
pituitary carcinomas remain rare, accounting for only 0.2%
of pituitary tumors, but are associated with 1-year mortality
rates of up to 66% (67). In a 2016 European Society of
Endocrinology (ESE) survey of treatment of aggressive
pituitary tumors, the mortality rate for APA nearly
approaches that of pituitary carcinomas, demonstrating the
need for improved chemotherapy and targeted molecular
therapies for these challenging tumors (68,69).
Recently, significant advances have been made in
understanding the genetic landscape of pituitary adenoma
tumorigenesis. The primary pathomechanism of pituitary
adenomas appears to involve alterations in cell-cycle
regulation and growth factor signaling due to epigenetic
changes. Somatic and germline mutations occur more
rarely with growth-hormone and ACTH-secreting
adenomas carrying somatic mutations in the GNAS and
USP8 genes, respectively (70). Mutations in USP48 and
BRAF have also been identified in USP8-negative Cushing’s
© Chinese Clinical Oncology. All rights reserved.

disease patients (71). More rarely, germline mutations
occur in association with familial tumor syndromes
including multiple endocrine neoplasia type 1 (MEN1)
and type 4 (MEN4) syndromes, Carney complex, and
McCune-Albright syndrome (70). While the identification
of germline and somatic genetic defects has contributed to
our understanding of PA pathogenesis, the exact molecular
mechanisms leading to the majority of PA remains to be
fully elucidated and the distinction of these molecular
subgroups has remained of limited clinical relevance in
terms of treatment.
Given the complex genomic landscape of PA, a wide
variety of therapies have been tried for aggressive pituitary
adenomas and carcinomas, mostly with poor results. To
date, the most commonly utilized therapies have been
alkylating chemotherapeutics previously approved for other
central nervous system malignancies. In 2006, a series of
case reports described regression of aggressive pituitary
adenomas following administration of temozolomide
(TMZ) monotherapy (72,73). More recently, McCormack
and colleagues reported the results of a European Society
of Endocrinology (ESE) survey on the treatment of APA
and PC (69). The survey included 157 patients treated with
TMZ as first-line chemotherapy reported that overall 37%
of patients demonstrated a radiographic response including
6% with complete regression. The majority of these
patients were administered TMZ according to the standard
Chin Clin Oncol 2020;9(6):75 | http://dx.doi.org/10.21037/cco-20-168
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Figure 3 A 63-year-old man presented with worsening diabetes mellitus and visual loss. Laboratory evaluation revealed an elevated growth
hormone (GH) of 53 ng/mL (<10.0) and a pituitary macroadenoma (arrow) with suprasellar extension on sagittal (A) and axial (B) MRI.
He underwent a right craniotomy for near-gross total resection of the mass followed by stereotactic radiosurgery with his postoperative
GH decreased to 3.7 ng/mL. Three years after treatment, laboratory and imaging surveillance revealed his GH increased to 134 and MRI
showed no sellar recurrence (C) but non-contiguous growth of his pituitary tumor (D) along the right sphenoid wing (*) consistent with
pituitary carcinoma.

“Stupp” protocol used for glioblastoma (TMZ 75 mg/m2
daily, followed by TMZ 150–200 mg/m2 daily for five days
every 28 days). The median duration of treatment was
9 months and the maximal radiographic response occurred
within 3 months in 23% of patients and within 6 months
in 59% of patients (74). Hormonally functioning tumors
responded better to TMZ than NFPA, and similar to the
responses seen with glioblastoma, lower activity levels of the
DNA repair enzyme 0(6)-methylguanine methyltransferase
(MGMT) were associated with improved clinical
response (69). On the basis of these results, the ESE
guidelines for the management of APA and PC currently
recommend use of TMZ monotherapy as first-line
chemotherapy for these tumors following documented
tumor growth (64). The ESE recommends that
radiographic response be evaluated after three cycles of
TMZ and therapy continued for at least six months for
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tumors demonstrating clinical response or stability. Little
data is available on the long-term treatment of APA and PC,
but TMZ monotherapy is often continued until progression
is observed.
There is limited data to guide second-line therapies
for APA and PC that continue to progress following
TMZ administration. Preclinical and clinical studies have
identified several pituitary adenoma-intrinsic targets for
therapy including growth factors and their receptors and
intracellular signaling pathways. Inhibition of VEGF has
been reported in 13 cases, with 9 cases showing apparent
clinical response to either anti-VEGF monotherapy or
combination therapy (TMZ, pasireotide, radiotherapy) (68).
Markers of tumor angiogenesis, including VEGF
expression, have been observed in APA compared to
standard pituitary adenomas. Ortiz et al. described a
patient with a silent corticotroph pituitary carcinoma who
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had progressed despite TMZ administration treated with
bevacizumab. After 26 months of bevacizumab treatment,
stability of disease was observed on serial MRI and PET
scan imaging (75). Wang et al. reported a >90% tumor
size reduction of a multiply recurrent aggressive growth
hormone-producing adenoma following treatment with
TMZ and the VEGFR-2 inhibitor apatinib (76). After two
years of follow-up, they reported sustained biochemical
growth hormone remission and no radiographic tumor
recurrence. The relative contribution of apatinib to the
clinical response remains uncertain, however. Based on
these limited data, VEGF-targeted therapies should be
considered in patients with progressive disease. The clinical
relevance of increased VEGF-expression as a biomarker
to predict response deserves further evaluation. The Raf/
MEK/ERK and PI3K/Akt/mTOR pathways have also
been shown to be upregulated in pituitary tumors (64,77).
Inhibitors of these cascades demonstrate anti-tumor effects
in vitro and in murine models of APA, however, limited
success has been observed clinically with these agents.
Everolimus, an oral mTOR inhibitor, has been employed as
second- or third-line monotherapy in five patients without
success (64,78). The oncogenic V600E BRAF mutation has
been detected in 16.5% of corticotroph adenomas but not
in other types of pituitary adenomas. Treatment of murine
corticotroph pituitary adenomas with the BRAF inhibitor
vemurafenib reduced ACTH expression, suggesting a role
for this inhibitor in Cushing’s disease patients with BRAFmutated tumors (68,71).
An additional emerging therapy for treatment refractory
pituitary adenomas is the use of immunotherapy. A recent
study by Wang et al. reported that PD-LI, a key predictive
marker of immunotherapy response, is frequently expressed
in functional pituitary adenomas with higher Ki-67
index (79). PD-L1 expression was detected in 59% of
functional tumors compared to 34% of NFPA. Similarly,
Mei et al. showed significantly higher levels of PDL1 expression and tumor infiltrating lymphocytes in
functional tumors, further raising the possibility that
checkpoint blockade immunotherapy may be effective in
cases of functional adenomas refractory to conventional
management (80). Currently, only a single case has been
reported of a patient with a pituitary carcinoma, previously
treated with TMZ and capecitabine, responding to
treatment with a combination of the checkpoint inhibitors
monoclonal antibodies nivolumab (anti-PD-1) and
ipilimumab (anti-CTLA4). Following five cycles of therapy,
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the intracranial tumor volume decreased by 59% and the
primary liver metastasis decreased by 92% (81). Plasma
ACTH levels decreased from 45,550 to 66 pg/mL. At
six months of surveillance, no progression was observed.
Importantly, clinical experience with immunotherapy
suggests that normal pituitary cells are susceptible to
checkpoint inhibitors with hypophysitis reported as a
common side effect of therapy in 4–15% of patients,
potentially related to ectopic expression of CTLA-4 on
pituitary endocrine (82-84). While this expression may
potentiate the anti-tumor immune response of checkpoint
inhibitors, patients will need to be closely monitored for
development of hypopituitarism.
In conclusion, following failure of conventional
treatments including surgical resection by an expert
neurosurgeon and maximal radiation therapy for aggressive
pituitary adenomas and pituitary carcinomas, TMZ is
currently recommended as first-line therapy. Secondand third-line options remain uncertain with limited data
available to guide therapy, however, treatment with VEGF
inhibitors and immune checkpoint inhibitors appear to
hold promise and are currently being investigated in several
clinical trials.
Craniopharyngiomas
Craniopharyngiomas are benign (WHO grade I) tumors
that occur in the sellar and suprasellar region, arising from
embryonic epithelium derived from Rathke’s pouch (85).
Craniopharyngiomas are relatively rare tumors with an
incidence of 0.13 per 100,000-person years and account for
3% of all intracranial neoplasms (1). Craniopharyngiomas
reliably occur in a bi-modal age distribution, most often
presenting in pediatric patients between the age of 5–14,
with a second peak occurring in adults in their sixth to
seventh decade of life (86). There are two subtypes of
craniopharyngiomas, each with a predilection to occur
in different patient populations: the adamantinomatous
subtype most frequently affects pediatric patients, whereas
papillary subtype predominantly occurs in adults (87).
Radiographically, adamantinomatous craniopharyngiomas
contain prominent cystic components and frequently
exhibit calcifications, whereas the papillary subtype is more
solid and rarely contains calcifications (88). Given their
location in the suprasellar space, craniopharyngiomas may
exert mass effect on nearby structures, and consequently
can present with vision changes from compression of the
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optic apparatus, hormonal abnormalities secondary to
hypothalamic-pituitary dysfunction, or headaches due to
obstructive hydrocephalus (89).
Craniopharyngiomas are slow-growing tumors and
diagnosis is often delayed until patients begin exhibiting
symptoms due to compression of adjacent structures. The
most common clinical symptoms at the time of diagnosis
include headaches, visual impairment, and endocrine
dysfunction (90). Pediatric patients are frequently
found to have endocrinopathies at the time of diagnosis,
most commonly growth hormone and gonadotrophin
deficiency (90). Adults, on the other hand, more often
present with headaches and visual field defects (91).
The treatment of craniopharyngiomas in both pediatric
and adult patients typically involves surgical resection
followed by adjuvant radiation therapy. Surgical resection
serves to reduce tumor mass effect on the optic apparatus
and brainstem as well as restore cerebrospinal flow to relieve
hydrocephalus. Resection also provides tissue diagnosis for
histopathology and molecular genotyping and decreases the
overall tumor volume for subsequent radiation treatment
if necessary (92). Surgical resection can be performed via a
transcranial or endoscopic endonasal approach (93), both
of which have shown to confer similar overall survival
when combined with adjuvant radiation therapy (94-96).
Radiation treatment has been shown to be an effective
adjuvant treatment following subtotal tumor resection or at
the time of tumor recurrence (97-99).
Surgical resection and radiation therapy provide
excellent tumor control, with overall 10-year survival
rates reported between 80–90%, albeit local recurrence
is common (100,101). Even amongst patients with longterm progression free survival, there is a high prevalence
of neurological and psychological morbidity. Patients
with craniopharyngioma diagnosed in childhood, and
their caregivers, report inferior quality of life metrics,
and harbor long-term psychosocial impairment (102).
Furthermore, pituitary insufficiency is present in a
large portion of patients, and up to 75% of patients are
rendered with panhypopituitarism, predisposing them to
chronic morbidity from obesity, hyperlipidemia, diabetes,
and cardiovascular disease (103). The neurocognitive
and metabolic morbidity associated with treatment of
craniopharyngiomas via aggressive surgical resection and
subsequent radiation therapy underscores the need for
research and development of novel drug therapies. In recent
years, insights gained from the molecular mechanisms that
drive pathogenesis of craniopharyngiomas have introduced
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the possibility that targeted therapies may developed for the
treatment of these tumors.
CTNNB1/β-catenin gene mutation in adamantinomatous
craniopharyngioma
A mutation of CTNNB1 resulting in the over-expression
β-catenin, mediated via activation of the Wnt signaling
pathway, has been implicated in the tumorigenesis of
adamantinomatous craniopharyngiomas (104). β-catenin
is a protein encoded by the CTNNB1, and is part of
the cadherin protein complex that mediates cellular
adhesion (105). β-catenin also comprises an important
part of the Wnt signaling pathway, which mediates cellular
proliferation. Aberrations in the β-catenin/Wnt signaling
pathway have been implicated in the pathogenesis of breast,
colorectal, and endometrial cancer (106). In its inactivated
form, β-catenin is found in the cellular membrane, where
it can be readily degraded by proteasomes. Mutations in
the CTNNB1 has been shown to activate the Wnt pathway,
which renders β-catenin resistant to degradation and instead
mobilizes β-catenin to the nucleus of cells to promote
tumor cell migration (107).
Sekine et al. performed DNA sequencing analysis on 16
patients who underwent resection of craniopharyngiomas
and found that all ten adamantinomatous specimens
harbored β-catenin gene mutations, which was not
found in any of the papillary subtype samples (108).
Immunohistological analysis revealed the cellular location
of β-catenin, too, was significantly different between the
two subtypes. The adamantinomatous subtype showed
predominantly cytoplastic and nuclear expression of
β-catenin, with lack of membranous staining, in contrast
to papillary subtype specimens that exclusively harbored
β-catenin in cellular membranes. Taken together, this
study was the first to show that in addition to separate
histologic findings between the two tumor subtypes,
adamantinomatous craniopharyngiomas harbor a distinct
genetic profile compared to papillary craniopharyngiomas,
with different underlying mechanisms of tumorigenesis
(Table 1).
The exon 3 location of the CTTNB1 encodes for the
glycogen synthase kinase-3 (GSK-3) domain responsible
for the phosphorylation of β-catenin, and mutations in this
gene prevent the protein from effectively being marked for
proteolysis. Goschzik et al. examined whether the CTTNB1/
β-catenin mutation at different phosphorylation sites
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Table 1 Clinical and genetic characteristics of adamantinomatous and papillary subtypes of craniopharyngioma
Adamantinomatous

Papillary

Age at presentation

Bimodal: predominantly in children, and in some
adults

Adults

Radiographic features

Frequently with calcifications and cysticcomponents

Often lacks calcifications and/or cystic components

Histologic characteristics

Whorls of palisading columnar epithelium; “wet”
keratin

Squamous epithelium

Genetic aberration

CTNNB1 mutation (Wnt signaling pathway)

BRAF (V600E) mutation (MAP kinase/ERK signaling
pathway)

corresponded to variable clinical behavior of these tumors,
and found that among five sites of somatic mutation there
was no significant difference in progression-free survival;
however, there was a trend towards poorer outcome amongst
patients who harbored mutations at the Thr41 site though
its significance was limited by small sample size (109).
Guadagno et al. investigated markers that predicted
increased risk of recurrence, and found that increased
immunohistochemical expression tumor cell clusters
containing β-catenin was associated with a higher rate of
recurrence (110).
The presence of CTTNB1/β-catenin mutations that
result in Wnt pathway activation has been corroborated as
being a key marker in the pathogenesis and progression
of adamantinomatous craniopharyngiomas, and studies
are underway investigating this gene mutation as a target
for therapeutic drug development (111). Furthermore,
the discovery of β-catenin mutations as a principal
factor in the clinical behavior of adamantinomatous
craniopharyngiomas underscores the need for genetic testing
and immunohistochemical staining to serve as important
adjuncts in the pathologic diagnosis of these tumors as well
as potentially predict clinical outcome. Although there are
no clinical trials currently available for adamantinomatous
craniopharyngiomas, several phase I and phase II trials are
underway investigating Wnt/β-catenin signaling inhibitors
to treat other solid tumors (112), and the results of these
studies may readily be translatable to craniopharyngiomas
given the same underlying disease pathogenesis.
BRAF (V600E) mutation in papillary craniopharyngioma
Brastianos et al. first reported the presence of V600E BRAF
oncogene mutation, with resultant activation of the MAP
kinase/ERK signaling pathway, as a crucial underlying
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aberration that drives the pathogenesis of papillary
craniopharyngiomas (113). Using whole exome sequencing
analysis, V600E BRAF mutations were identified in all
three ‘discovery’ papillary craniopharyngioma specimens
(including one from a pediatric patient). None of these were
found to harbor CTNNB1/β-catenin mutations. This finding
was corroborated by performing targeted genotyping in a
larger cohort, and BRAF mutations were detected in 95%
of papillary craniopharyngiomas. Although it was already
widely believed that the two subtypes of craniopharyngioma
have distinct underlying genetic attributes, this study
was the first to report the specific mutation driving the
pathogenesis of the papillary subtype, thereby identifying a
potential target for therapeutic drug treatment.
Since this crucial discovery, several case reports have
been published that report a marked response to treatment
of papillary craniopharyngiomas using BRAF inhibitors.
Aylwin et al. were the first to report the successful
treatment response of recurrent craniopharyngioma with
the use of vemurafenib, a BRAF inhibitor. In their case
report, a patient with histologically-confirmed papillary
craniopharyngioma who had previously undergone three
endoscopic tumor resections and adjuvant radiation
therapy presented with tumor recurrence. The patient was
treated with vemurafenib for three months, and repeat
MRI showed a dramatic reduction in tumor size after two
weeks. However, the tumor recurred within six weeks after
treatment was discontinued (114). Brastianos et al. published
a case report of a patient with recurrence of a large, cystic
tumor who was treated with dual BRAF (dabrafenib) and
MEK (trametinib) inhibitors, with resultant decrease of
over 80% in the size of the tumor. Following this treatment,
the patient’s tumor was amenable to endoscopic resection,
and with adjuvant radiosurgery, the authors report that he
remained symptom-free 18 months after treatment (115).
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In another case study, Rostami et al. reported near
resolution of tumor four months after initiating treatment
with dual MEK and BRAF inhibitors. The treatment
was discontinued after the patient developed pyrexia, and
the subsequent clinical course, including whether tumor
recurrence occurred, was not reported (116).
The BRAF inhibitor vemurafenib is currently FDAapproved for the treatment of late-stage melanoma, which
frequently harbors the same V600E mutation as papillary
craniopharyngioma. In one randomized phase III clinical
trial, patients receiving vemurafenib had significantly longer
overall survival compared to the chemotherapeutic agent
dacarbazine (117). In another phase III trial for metastatic
melanoma, a separate BRAF inhibitor (dabrafenib) and
adjunct MEK inhibitor (trametinib) was shown to improve
overall survival compared to BRAF inhibitor monotherapy,
suggesting that the addition of a MEK inhibitor can protect
against BRAF inhibitor resistance (118). However, the
response of BRAF inhibitors to treat other types of tumors
has been more guarded. Hyman et al. conducted a phase II
study that investigated tumor response to vemurafenib in a
variety of non-melanoma cancers harboring BRAF V600E
mutations and found a highly variable tumor response. This
study highlights that although targeted therapies can be
developed to treat tumors harboring specific mutations, the
sensitivity of response may vary between different types of
tumors (119).
Given that there has been a singular underlying
mutation identified that drives the pathogenesis of
papillary craniopharyngiomas, the use of targeted drug
therapy holds great promise for the treatment of this
tumor. There is a phase II clinical trial currently underway
(NCT03224767) investigating the combined use of BRAF
and MEK-inhibitors (vemurafenib and cobimetinib) for the
treatment of BRAF V600E mutant residual or recurrent
craniopharyngiomas. Given the long-term morbidity
associated with the current management paradigm for
craniopharyngiomas, development of a targeted treatment
for patients with BRAF V600E mutant papillary subtype
tumors could serve not only for the treatment of recurrent
tumors, but also potentially as a neoadjuvant therapy to
reduce tumor size prior to surgery or radiation and limit the
long-term morbidity associated with these treatments.
Discussion
There is a paucity of effective agents for refractory
or relapsed meningioma, pituitary adenoma, or
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craniopharyngioma, though a new focus on investigating
tumorigenic drivers has resulted in the development
of promising therapies, particularly for NF-2 mutated
meningiomas and craniopharyngiomas harboring mutations
of V600E BRAF. In contrast, NF-2 wild-type meningiomas
often exhibit a high mutational burden which may be
more responsive to immunotherapy. Clarification of the
genetic and epigenetic changes which drive development of
pituitary adenomas is still developing, though the inverse
relationship between MGMT immunoexpression and the
response to temozolomide warrants interest.
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